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One approach to the identification of genetic loci that influence complex diseases is through the study of quantitative
risk factors correlated with disease susceptibility. Factor XII (FXII) plasma levels, a related phenotype correlated
with thrombosis, is such a risk factor. We conducted the first genomewide linkage screen to localize genes that
influence variation in FXII levels. Two loci were detected: one on chromosome 5 and another on chromosome 10
(LOD scores 4.73 and 3.53, respectively). On chromosome 5, the peak LOD score occurred in the 5q33-5ter region,
near the FXII gene. Addition of a 46C/T mutation in the FXII gene increased the multipoint LOD score to 10.21
( ). A bivariate linkage analysis of FXII activity and thrombosis further improved the linkage signal512Pp 3.6 # 10
(LOD p 11.73) and provided strong evidence that this quantitative-trait locus (QTL) has a pleiotropic effect on
the risk of thrombosis ( ). Linkage analysis conditional on 46C/T indicated that this mutation alone cannotPp .004
explain the chromosome 5 signal, implying that other functional sites must exist. These results represent the first
direct genetic evidence that a QTL in or near the FXII gene influences both FXII activity and susceptibility to
thrombosis and suggest the presence of one or more still unknown functional variants in FXII.
Introduction
Thrombosis is a common cause of morbidity and mor-
tality in industrialized nations. Both venous and arterial
thrombosis can be life-threatening events, and both are
of great public health importance. Although there is little
direct information on prevalence, retrospective and pro-
spective data (Coon et al. 1973; Nordstrom et al. 1992;
Anderson et al. 1991) suggest a minimum lifetime prev-
alence of 5%–10% for deep-vein thrombosis alone. Af-
ter the inclusion of arterial thromboses, other venous
thromboses, and undiagnosed thrombotic conditions,
the true lifetime prevalence of thrombosis must be sub-
stantially larger than 10%.
The canonical causes of thrombosis include both en-
vironmental and genetic factors. The high prevalence of
thrombosis and its known environmental influences
(e.g., oral contraceptive use) suggest that multiple genes
of varying effects will be involved in determining sus-
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ceptibility to thrombosis. There are several well-char-
acterized genetic defects that lead to increased throm-
botic risk (Lane et al. 1996). However, very little
information is available on the relative importance of
genetic factors in thrombosis risk in the general popu-
lation. Moreover, it is unlikely that these known mu-
tations, with their comparatively low frequencies, con-
stitute the primary genetic influences on the risk of
common late-onset thrombosis. Recently, as part of the
GAIT (Genetic Analysis of Idiopathic Thrombophilia)
project, we quantified the genetic component of sus-
ceptibility to thrombosis and related phenotypes (Souto
et al. 2000a, 2000b). Among the clotting factors stud-
ied, factor XII (FXII) levels exhibited one of the highest
heritabilities (67%) and a significant positive genetic
correlation (0.351) with thrombotic disease (Souto et
al. 2000a), indicating that some of the genes that
influence variation in this physiological risk factor
also influence liability to thrombosis. Therefore, we
performed a genome scan to identify genes influenc-
ing FXII levels. To our knowledge, our study repre-
sents the first genomewide scan undertaken to iden-
tify regions containing genes that influence variation
in susceptibility to thrombotic disease and its inter-
mediate phenotypes. The identification of such
regions and genes may help to elucidate the mecha-
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nism underlying the risk of common thrombosis and
therefore may suggest preventive strategies to reduce
thrombosis-related morbidity and mortality.
Subjects and Methods
Subjects and Phenotypes
The recruitment, sampling, and phenotyping methods
used in the GAIT project have been extensively described
elsewhere (Soria et al. 2000; Souto et al. 2000b;). In
brief, the sample included 21 families (398 individuals)
selected primarily for pedigree size, to maximize the
power to detect genetic effects. To be included, a family
was required to have 10 living individuals in three or
more generations. Twelve families were selected through
a proband with idiopathic thrombophilia, which was
defined as a personal history of multiple thrombotic
events (at least one of which spontaneous), a history of
a single spontaneous episode of thrombosis plus a first-
degree relative who was also affected, or onset of throm-
bosis at !45 years of age. Of the 12 probands, 10 had
onset at age !45 years, 8 experienced multiple throm-
boses, and only 2 were ascertained because of a single
episode of thrombosis with a relative also affected. Di-
agnoses of the thrombophilic probands were verified
by objective methods. A proband’s thrombophilia was
considered idiopathic if all known (during the re-
cruitment period of 1995–1997) biological causes
(e.g., antithrombin deficiency, protein S and C deficien-
cies, activated protein C resistance, plasminogen defi-
ciency, heparin cofactor II deficiency, Leiden factor V,
dysfibrogenemia, lupus anticoagulant, and antiphospho-
lipid antibodies) of thrombophilia were excluded. These
thrombophilic factors were also absent in all affected
relatives. The remaining 9 of the 21 families were se-
lected without regard to phenotype.
FXII was assayed using deficient plasma from Diag-
nostica Stago (Asnie`res) by automated coagulometry as
described elsewhere (Souto et al. 2000b). To reduce mea-
surement error, assays were performed in duplicate, and
the average value calculated for each person. The inter-
assay coefficient of variation was estimated in 5.5%.
All procedures were reviewed by the institutional re-
view board of the Hospital de la Santa Creu i Sant Pau
(Barcelona). Adult subjects gave informed consent for
themselves and their minor children.
Genotypes
DNA was extracted using a standard protocol (Miller
et al. 1988). The present genome scan used a total of
363 highly informative microsatellite markers, spaced at
∼9.5 cM. The microsatellites consisted primarily of the
ABI-Prism genotyping set MD-10. Linkage mapping was
undertaken, using multiplex PCR with the PE LMS II
fluorescent marker set; in a few instances, nearby Ge´-
ne´thon markers were substituted for LMS II markers, to
improve robustness. The PCR products were analyzed
on PE 310, PE 377, and PE 3700 automated sequencers
and were genotyped using the PE Genotyper software.
Information on microsatellite markers can be found in
the publicly accessible Genome Database. The average
heterozygosity of these markers was 0.79.
Markers in or near several hemostasis-related candi-
date genes were used to augment this genome scan. The
46T/C polymorphism in the FXII gene was amplified as
reported elsewhere (Kanaji et al. 1998), with minor mod-
ification. In brief, we used SfaNI, which provided better
resolution of the digested bands. The genotypic data
were entered into a database and were analysed for dis-
crepancies (i.e., violations of Mendelian inheritance), us-
ing the INFER (PEDSYS) program (Dyke 1995). Dis-
crepancies were checked in the laboratory for mistyping,
and markers for discrepant individuals were either cor-
rected or excluded from the analysis.
Linkage Analysis
Standard oligogenic multipoint variance-component
linkage methods, as implemented in the SOLAR soft-
ware program, were used for the genome scan (Almasy
and Blangero 1998). Previous studies have suggested
that such methods may be vulnerable to deviations from
multivariate normality and particularly to high levels of
kurtosis in the trait distribution (Allison et al 1999).
Levels of FXII in the GAIT sample exhibited a kurtosis
of 0.05. Recent statistical genetic theory demonstrates
that this level of kurtosis will not affect the distribution
of LOD scores and that the standard nominal P values
for LOD scores are appropriate for the FXII linkage
screen (Blangero et al. 2000). Allele frequencies were
estimated from the GAIT sample, and marker maps for
multipoint analyses were obtained from ABI-Prism and
from the Marshfield Center for Medical Genetics. Be-
cause 12 of the families were ascertained through throm-
bophilic probands, all analyses included an ascertain-
ment correction achieved by conditioning the likelihood
of these pedigrees on the likelihoods of their respective
probands (Boehnke and Lange 1984). genomewide P
values were calculated using the method of Feingold et
al. 1993. Bivariate linkage analyses using the mixed dis-
crete/continuous trait multivariate model were con-
ducted with a modified version of SOLAR (Williams et
al. 1999).
Measured Genotype and Conditional Linkage Analyses
Quantitative-trait association analysis was performed
using the measured genotype approach (Hopper and
Mathews 1982) by testing for genotype-specific differ-
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Table 1
Results from the Initial and Conditional Genomewide Linkage
Screens of FXII
CHROMOSOME
POSITION
(cM)
LOD SCORE FOR
First Pass Second Pass Third Pass
5 193 4.73 … …
10 38 3.53 3.43 …
2 9 2.26 1.83 .59
11 10 1.30 .44 .19
14 63 1.16 .75 .90
15 79 1.03 .41 .35
NOTE.—All loci with LOD scores 11.0 in the initial pass are shown.
The second linkage pass was conditional on a locus on chromosome
5q, and the third pass was conditional on loci on 5q and 10p.
Figure 1 Results of the initial linkage screen
ences in the means of traits while allowing for the non-
independence among family members. These analyses
were performed using SOLAR (Almasy and Blangero
1998). To assess linkage conditional on the observed
association (Amos 1994), an extension of the variance-
component–based linkage test was performed by si-
multaneously incorporating the genotype-specific means
of the measured genotype test and estimating a linkage
component.
Results
Multipoint variance-component methods were used to
assess linkage between highly informative autosomal
DNA markers, spaced at ∼9.5 cM, and plasma levels of
FXII. The results of the initial FXII linkage screen are
shown in figure 1 and table 1. The linkage analysis re-
vealed strong evidence that quantitative-trait loci (QTLs)
on chromosomes 5q influence FXII levels (LODp 4.73;
nominal ; genomewide ), as6Pp 1.5 # 10 Pp .00046
do QTLs at chromosome 10p (LOD p 3.43, nominal
; genomewide ). Additionally,5Pp 3.5 # 10 Pp .0114
suggestive evidence of linkage (LOD scores of 1.0–2.3)
were observed on chromosomes 2p, 11p, 14q, and 15q.
Given the strong evidence for multiple QTLs that influ-
ence FXII levels, we performed a series of multilocus
linkage screens, in which QTLs were sequentially in-
corporated into the linkage model and the genome
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Figure 2 Initial and conditional LOD scores on chromosome 10
Figure 3 Detailed linkage results for chromosome 5
was rescreened (table 1). In the second linkage pass,
which was conditional on the chromosome 5 QTL that
was detected in the initial screen, evidence for a QTL
on chromosome 10 remained strong (LOD p 3.43),
whereas LOD scores in other regions that previously
showed suggestive linkage declined slightly. Conditional
on the chromosome 5 and 10 QTLs, little evidence for
additional QTLs remained in a third linkage screen (all
LOD scores ! 1.0).
The peak LOD score on chromosome 10 occurred
between markers D10S189 and D10S1653 in the10p13
region (fig. 2). On chromosome 5, the peak LOD score
occurred between markers D5S400 and D5S408 in a
region that maps to 5q33-5ter (fig. 3). Because the hu-
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Figure 4 Detailed linkage results for chromosome 5 when the 46C/T variant was added
man FXII gene has been mapped to this region (Royle
et al. 1988), we have genotyped a known polymorphism
in exon 1 of the FXII gene (46C/T). In the present study,
we found 264 homozygotes for the common variant (C/
C), 117 heterozygotes (C/T), and 11 homozygotes (T/
T); the maximum-likelihood estimate of the frequency
of the T allele was 0.21. If Hardy-Weinberg equilibrium
is assumed, this allele frequency predicts a heterozygote
frequency of 0.331.
When this variant was added to the chromosome 5
linkage map, the multipoint LOD score increased dra-
matically to 10.21 ( ; fig. 4). The results12Pp 3.6 # 10
support the presence of a major QTL in the region of
the FXII gene. Given this unequivocal evidence for link-
age, we performed an association analysis to test for
linkage disequilibrium between the QTL and the 46C/
T variant. This measured-genotype–association anal-
ysis revealed significant differences among the three
46C/T genotypes in their plasma FXII values
( ; ; ; ).7CCp 128.9 CTp 92.2 TTp 55.6 P ! 1 # 10
Under the assumption that 46C/T affects the function
of the FXII locus, we calculated that this mutation
accounts for 40% of the variance in FXII activity
levels in this population.
Because our previous studies have suggested that FXII
levels are correlated with risk of thrombosis and that
this relationship is, in part, a result of genes that influ-
ence both traits (Souto et al. 2000a), we wished to test
whether either of the QTLs influencing FXII levels might
also contribute to genetic susceptibility to thrombosis.
This was accomplished through bivariate linkage anal-
ysis of FXII and thrombosis (Williams et al. 1999). Such
bivariate analyses with related phenotypes have been
shown to increase power to detect linkage (Soria et al.
2000). In the combined analysis of FXII levels and
thrombosis, the LOD score on chromosome 10 re-
mained at its previous level, providing no evidence that
this QTL influences thrombosis risk, whereas the LOD
score on chromosome 5 rose to 11.73, providing strong
evidence that this QTL has a pleiotropic effect on the
risk of thrombosis ( ).Pp .004
To determine whether the 46C/T marker could be the
functional QTL underlying our linkage signal, we per-
formed a conditional linkage analysis (Soria et al. 2000)
that simultaneously accounted for association with the
46C/T mutation. Conditional on 46C/T, evidence for
linkage to 5q still remained (LOD p 0.9; fig. 4), in-
dicating that, although 46C/T may be functional, there
must be one or more additional polymorphisms in the
same region that influence FXII levels and thrombosis
risk.
Discussion
Our results represent the first genomewide scan under-
taken to identify regions containing genes that influence
variation in susceptibility to thrombotic disease and their
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related phenotypes. Initial and subsequent conditional
passes of variance-component linkage analyses revealed
two regions, one on chromosome 5 and another on chro-
mosome 10, that showed strong evidence of linkage with
levels of plasma FXII, an important intermediate phe-
notype correlated with thrombosis (Souto et al. 2000a).
In the region of the linkage signal on chromosome
10, there are no obvious candidate hemostasis-related
genes. In contrast, we have documented the close link-
age between a QTL influencing FXII levels and the FXII
gene (specifically, the 46C/T FXII DNA variant). When
we added this genetic variant as a marker, a highly sig-
nificant LOD score of 10.21 was calculated, providing
strong evidence for the existence of a QTL that influ-
ences FXII activity.
Recent case-control studies demonstrated association
between the 46C/T polymorphism in exon 1 of the FXII
gene and variation in levels of FXII (Kanaji et al. 1998;
Ishii et al. 2000). In our study, under the assumption
that 46C/T is itself a functional QTL, we calculated that
this mutation accounts for 40% of the variance in
FXII activity levels in our population. If 46C/T is not
itself functional but is only in disequilibrium with an-
other site, this effect size may be an underestimate.
There remains substantial residual genetic variation in
FXII activity, even after taking into account the effects
of 46C/T. This indicates that there are other QTLs that
influence FXII activity level, as is suggested by the highly
significant linkage signal on chromosome 10. Moreover,
the residual linkage signal (LODp 0.9) in the combined
linkage/disequilibrium analysis (Soria et al. 2000), which
simultaneously allowed for association between the 46C/
T polymorphism and FXII levels, indicated that, although
46C/T may be functional, there must be one or more
additional polymorphisms in the region that influences
FXII levels. This result supports the observation we re-
ported elsewhere that multiple QTLs of varying effects
will be involved in determining variation in hemostasis-
related phenotypes (Souto et al. 2000a, 2000b).
In addition to our analyses, there is biochemical ev-
idence of a functional role of the 46C/T in the pheno-
typic variability of FXII levels. Kanaji et al. (1998) re-
ported that this mutation decreased the translation
efficiency and led to low plasma levels of FXII activity
and antigen, probably as a result of the creation of
another ATG codon and/or the impairment of the con-
sensus sequence for the translation-initiation scanning
model. On the basis of these biochemical results and
our linkage analyses, we expect that 46C/T is a func-
tional polymorphisms in FXII. To identify the other
variant(s), the next step is to catalog, by use of DNA
resequencing, the complete menu of DNA sequence var-
iation within the FXII gene. Because variation within
noncoding regions may influence the regulation of tran-
scription and other genetic functions, DNA resequenc-
ing should not be limited to the exons of the gene, but
should include 5′ and 3′ regulatory regions, as well as
introns. Because FXII consists of 13 introns and 14
exons that cover 12 kb (Cool and MacGillivray 1987),
this task may be attainable.
It is important to note that this study confirms and
extends our previous observation that FXII levels are
correlated with risk of thrombosis and that this rela-
tionship is due in part to genes that influence both traits
(Souto et al. 2000a). This was accomplished through
bivariate linkage analysis of FXII and thrombosis (Wil-
liams et al. 1999). Such bivariate analyses with related
phenotypes increase the power to detect linkage (Soria
et al. 2000). The combined analysis of FXII levels and
thrombosis risk substantially enhanced the linkage sig-
nal on chromosome 5, providing strong evidence that
this QTL has a pleiotropic effect on the risk of throm-
bosis. However, the LOD score on chromosome 10 re-
mained at its previous level, providing no evidence that
this QTL influences thrombosis risk. Our results con-
firm the valuable potential of this statistical approach
as a basic tool for mapping the genes that affect complex
diseases.
Despite the important putative role of FXII—which
is a serine protease precursor involved in the initiation
of the intrinsic coagulation pathway, in fibrinolysis, in
the generation of bradykinin, and in the complement
system (Kaplan and Silverberg 1987; Kluft et al.
1987)—its biologic role is not fully understood. Fur-
thermore, there is controversy over the clinical signifi-
cance of a decreased or increased FXII concentration
on venous and arterial thrombosis (Halbmayer et al.
1992; Helft et al. 2000). Further investigation of FXII
and other genes may enhance our understanding of the
factors influencing thrombosis, especially the chromo-
some 10p13 region, which should be targeted for fine
mapping, and gene-identification studies.
In conclusion, our study represents the first direct
genetic evidence that at least one QTL in the FXII gene
influences both FXII levels and susceptibility to throm-
bosis. Our results also support the conclusion that the
46C/T polymorphism, in addition to at least one other
unknown functional variant in the FXII gene, is likely
to be one of these QTLs. Therefore, variations in the
FXII gene should be considered as potential genetic risk
factors for thrombosis. However, exhaustive enumera-
tion of all potentially functional variants will be re-
quired to completely document the allelic architecture
of such thrombosis risk–related variation.
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